Meta-analysis of double-expressor lymphoma prognoses and novel therapies

Photo by CDC / Unsplash

Frontiers in Medicine Published May 22, 2026 Medically reviewed May 22, 2026 Study authors: Hao Guan, Zhihe Liu, Chengwen Gao, Wenqiu Wang, Kaiyue Liu, Xia Zhao DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider that DEL predicts worse survival in DLBCL, and Z+R-CHOP shows favorable toxicity but needs validation.

This is a systematic evaluation meta-analysis of 9,808 patients from 66 studies, focusing on diffuse large B-cell lymphoma (DLBCL) and double-expressor lymphoma (DEL). The authors compared DEL versus non-DEL and evaluated novel therapies including R-CHOP, DA-EPOCH-R, R2-CHOP, I+R-CHOP, Z+R-CHOP, and Ven-R-CHOP.

The key synthesized finding is that DEL was significantly associated with inferior progression-free survival (hazard ratio 1.78, 95% confidence interval 1.50–2.10) and inferior overall survival (hazard ratio 1.90, 95% confidence interval 1.68–2.15). Within DEL, high International Prognostic Index, advanced age, elevated lactate dehydrogenase, B symptoms, and advanced stage predicted inferior outcomes; TP53 mutation and poor Eastern Cooperative Oncology Group performance status predicted inferior OS.

Regarding novel regimens, the authors reported that Z+R-CHOP and Ven-R-CHOP showed the highest efficacy, and Z+R-CHOP demonstrated favorable hematological toxicity compared with other novel regimens. The analysis included 1,803 patients from 13 treatment studies.

The authors noted limitations, including that precise risk quantification and optimal treatments remain unclear. They concluded that Z+R-CHOP emerges as a promising strategy requiring validation in prospective studies, emphasizing cautious interpretation of the findings.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Double-expressor lymphoma (DEL), defined by concurrent MYC and BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL), is associated with poor prognosis, but precise risk quantification and optimal treatments remain unclear. We conducted a two-stage evidence synthesis. First, a systematic review and meta-analysis quantified hazard ratios for progression-free survival (PFS) and overall survival (OS) comparing DEL with non-DEL and identified prognostic factors within DEL. Second, a network meta-analysis ranked the efficacy and safety of regimens including rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R); R-CHOP plus lenalidomide (R2-CHOP); R-CHOP plus ibrutinib (I+R-CHOP); R-CHOP plus zanubrutinib (Z+R-CHOP); and R-CHOP plus venetoclax (Ven-R-CHOP). In 66 studies (9,808 patients), DEL was significantly associated with inferior PFS (hazard ratio 1.78, 95% confidence interval 1.50–2.10) and OS (1.90, 1.68–2.15). Within DEL, high International Prognostic Index, advanced age, elevated lactate dehydrogenase, B symptoms, and advanced stage predicted inferior PFS and OS; TP53 mutation and poor Eastern Cooperative Oncology Group performance status predicted inferior OS. In 13 treatment studies (1,803 patients), Z+R-CHOP and Ven-R-CHOP showed the highest efficacy. Z+R-CHOP demonstrated favorable hematological toxicity compared with other novel regimens. DEL is a distinct high-risk subtype with quantifiable prognostic detriment. Z+R-CHOP emerges as a promising strategy requiring validation in prospective studies.